|
ID26987A
(id)
*
|
1998-07-06 |
2001-02-22 |
Janssen Pharmaceutica Nv |
Inhibitor-inhibitor transferase protein farnesil dengan sifat-sifat peka terhadap sinar radiasi in vivo
|
|
TR200201296T2
(tr)
*
|
1999-02-11 |
2002-07-22 |
Pfizer Products Inc. |
Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
|
|
AU781986B2
(en)
*
|
1999-11-05 |
2005-06-23 |
Cytovia, Inc. |
Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
ES2212971T3
(es)
*
|
1999-11-30 |
2004-08-16 |
Pfizer Products Inc. |
Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa.
|
|
HN2000000266A
(es)
*
|
2000-01-21 |
2001-05-21 |
Pfizer Prod Inc |
Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
|
|
EP1253921A4
(en)
*
|
2000-01-28 |
2004-10-13 |
Merck & Co Inc |
TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS
|
|
JO2361B1
(en)
*
|
2000-06-22 |
2006-12-12 |
جانسين فارماسيوتيكا ان. في |
Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
|
|
EP1170011A1
(en)
*
|
2000-07-06 |
2002-01-09 |
Boehringer Ingelheim International GmbH |
Novel use of inhibitors of the epidermal growth factor receptor
|
|
JP4974439B2
(ja)
*
|
2000-09-25 |
2012-07-11 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
|
|
ATE409189T1
(de)
*
|
2000-09-25 |
2008-10-15 |
Janssen Pharmaceutica Nv |
Farnesyl transferase-hemmende 6- heterocyclylmethyl-chinolin und chinazol-derivate
|
|
US7053105B2
(en)
|
2000-09-25 |
2006-05-30 |
Janssen Pharmaceutica, N.V. |
Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
|
|
WO2002024683A1
(en)
|
2000-09-25 |
2002-03-28 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives
|
|
CN1703403A
(zh)
*
|
2000-10-02 |
2005-11-30 |
詹森药业有限公司 |
趋代谢的谷氨酸盐受体拮抗剂
|
|
ES2328225T3
(es)
|
2000-11-21 |
2009-11-11 |
Janssen Pharmaceutica Nv |
Derivados benzoheterociclicos inhibidores de la farnesil-transferasa.
|
|
EP1351954B1
(en)
*
|
2000-12-27 |
2006-05-03 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives
|
|
ATE319704T1
(de)
|
2000-12-27 |
2006-03-15 |
Janssen Pharmaceutica Nv |
Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
|
|
US6858607B1
(en)
|
2001-05-16 |
2005-02-22 |
Cytovia, Inc. |
7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
EP1392283A4
(en)
|
2001-05-16 |
2004-10-20 |
Cytovia Inc |
SUBSTITUTED CUMARINE AND CHINOLINE AS CASPASE ACTIVATORS
|
|
EP1392683B1
(en)
*
|
2001-05-16 |
2009-12-02 |
Cytovia, Inc. |
Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and their use as anticancer agents
|
|
WO2003006006A1
(en)
*
|
2001-07-09 |
2003-01-23 |
The Regents Of The University Of California |
Use of matrix metalloproteinase inhibitors to mitigate nerve damage
|
|
CA2469275C
(en)
|
2001-12-19 |
2011-09-06 |
Janssen Pharmaceutica N.V. |
1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
|
|
ES2287466T3
(es)
|
2002-03-22 |
2007-12-16 |
Janssen Pharmaceutica N.V. |
Derivados de 2-quinolinona y quinazolina de bencilimidazolil sustituidas como inhibidores de la farnesil transferasa.
|
|
NZ535438A
(en)
*
|
2002-03-29 |
2006-08-31 |
Janssen Pharmaceutica Nv |
Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
|
|
CA2481480C
(en)
|
2002-04-15 |
2011-04-12 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
|
|
US7476741B2
(en)
|
2002-05-16 |
2009-01-13 |
Cytovia, Inc. |
Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
CN100349887C
(zh)
|
2002-05-16 |
2007-11-21 |
西托维亚公司 |
取代的4－芳基－4h－吡咯并[2,3－h]色烯和类似物及其药物组合物和用途
|
|
US20040186160A1
(en)
*
|
2002-12-13 |
2004-09-23 |
Sugen, Inc. |
Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
|
|
AU2003286321A1
(en)
*
|
2002-12-19 |
2004-07-14 |
Pfizer Inc. |
2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
|
|
PT2476667E
(pt)
|
2003-02-26 |
2014-09-18 |
Sugen Inc |
Compostos de aminoheteroarilo como inibidores da proteína quinase
|
|
WO2004076446A1
(ja)
*
|
2003-02-27 |
2004-09-10 |
Chugai Seiyaku Kabushiki Kaisha |
ベンゾチオフェン誘導体
|
|
CA2533626A1
(en)
*
|
2003-07-22 |
2005-02-03 |
Janssen Pharmaceutica, N.V. |
Quinolinone derivatives as inhibitors of c-fms kinase
|
|
JP4691041B2
(ja)
|
2003-11-20 |
2011-06-01 |
チルドレンズ ホスピタル メディカル センター |
Ｇｔｐアーゼ阻害剤および使用方法
|
|
CA2559221A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
US20050288298A1
(en)
*
|
2004-03-18 |
2005-12-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
WO2005089515A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
CA2559285A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
|
BRPI0509580A
(pt)
*
|
2004-03-30 |
2007-11-27 |
Pfizer Prod Inc |
combinações de inibidores de transdução de sinal
|
|
JP4242911B2
(ja)
|
2004-08-26 |
2009-03-25 |
ファイザー・インク |
プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
|
|
EP1786777A1
(en)
*
|
2004-08-26 |
2007-05-23 |
Pfizer, Inc. |
Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
|
|
CA2577937C
(en)
*
|
2004-08-26 |
2010-12-21 |
Pfizer Inc. |
Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
|
|
WO2006041900A2
(en)
*
|
2004-10-07 |
2006-04-20 |
Cytovia, Inc. |
SUBSTITUTED N-ARYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS
|
|
WO2007016539A2
(en)
|
2005-07-29 |
2007-02-08 |
Children's Hospital Medical Center |
Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
|
|
SI2447283T1
(sl)
|
2005-09-07 |
2015-12-31 |
Amgen Fremont Inc. |
Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1 (ALK-1)
|
|
AU2006292278B2
(en)
|
2005-09-20 |
2012-03-08 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
AU2006331542A1
(en)
|
2005-12-23 |
2007-07-05 |
Link Medicine Corporation |
Treatment of synucleinopathies
|
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
|
EA200802058A1
(ru)
|
2006-05-09 |
2009-06-30 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и их фармацевтические композиции
|
|
AU2007287794B2
(en)
|
2006-08-21 |
2013-03-28 |
F. Hoffmann-La Roche Ag |
Tumor therapy with an anti-VEGF antibody
|
|
RU2472788C9
(ru)
*
|
2007-05-23 |
2013-04-20 |
Аллерган, Инк. |
(бициклогетероарил)имидазолил)метилгетероарильные соединения как агонисты адренергических рецепторов
|
|
PL2155733T3
(pl)
*
|
2007-05-23 |
2013-02-28 |
Allergan Inc |
Cykliczne laktamy do leczenia jaskry lub podwyższonego ciśnienia śródgałkowego
|
|
US8129356B2
(en)
*
|
2007-10-01 |
2012-03-06 |
Vanderbilt University |
Bmx mediated signal transduction in irradiated vascular endothelium
|
|
WO2009151683A2
(en)
*
|
2008-03-12 |
2009-12-17 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
|
DE102008022221A1
(de)
*
|
2008-05-06 |
2009-11-12 |
Universität des Saarlandes |
Inhibitoren der humanen Aldosteronsynthase CYP11B2
|
|
AU2009313927A1
(en)
*
|
2008-11-13 |
2010-05-20 |
Astrazeneca Ab |
Azaquinolinone derivatives and uses thereof
|
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
|
SG172857A1
(en)
*
|
2009-02-09 |
2011-08-29 |
Supergen Inc |
Pyrrolopyrimidinyl axl kinase inhibitors
|
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
|
WO2010098866A1
(en)
|
2009-02-27 |
2010-09-02 |
Supergen, Inc. |
Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
AU2011223655A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
AU2011223643A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
|
|
DK2734205T3
(en)
|
2011-07-21 |
2018-06-14 |
Tolero Pharmaceuticals Inc |
Heterocyclic Protein Kinase Inhibitors
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
US9980942B2
(en)
|
2012-05-02 |
2018-05-29 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
|
MY189505A
(en)
|
2012-10-16 |
2022-02-16 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of roryt
|
|
WO2014062655A1
(en)
|
2012-10-16 |
2014-04-24 |
Janssen Pharmaceutica Nv |
HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
|
|
HK1213887A1
(zh)
|
2012-10-16 |
2016-07-15 |
Janssen Pharmaceutica N.V. |
RORγt的苯基连接的喹啉基调节剂
|
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
|
PT2970205T
(pt)
|
2013-03-14 |
2019-08-26 |
Tolero Pharmaceuticals Inc |
Inibidores da jak2 e da alk2 e métodos para a sua utilização
|
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
|
US9284308B2
(en)
|
2013-10-15 |
2016-03-15 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of RORγt
|
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
|
US10555941B2
(en)
|
2013-10-15 |
2020-02-11 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORγt
|
|
CA2926339A1
(en)
|
2013-10-15 |
2015-04-23 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of roryt
|
|
CA2927182A1
(en)
|
2013-10-15 |
2015-04-23 |
Janssen Pharmaceutica Nv |
Quinolinyl modulators of ror.gamma.t
|
|
US9403816B2
(en)
|
2013-10-15 |
2016-08-02 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of RORγt
|
|
US9328095B2
(en)
|
2013-10-15 |
2016-05-03 |
Janssen Pharmaceutica Nv |
Heteroaryl linked quinolinyl modulators of RORgammat
|
|
US10028503B2
(en)
|
2014-06-18 |
2018-07-24 |
Children's Hospital Medical Center |
Platelet storage methods and compositions for same
|
|
WO2017096165A1
(en)
|
2015-12-03 |
2017-06-08 |
Agios Pharmaceuticals, Inc. |
Mat2a inhibitors for treating mtap null cancer
|
|
CN108003150A
(zh)
*
|
2016-10-31 |
2018-05-08 |
河南工业大学 |
4-杂芳基喹啉酮衍生物的制备方法及其应用
|
|
KR20210038906A
(ko)
|
2018-07-26 |
2021-04-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
|
|
HUE072069T2
(hu)
|
2019-02-12 |
2025-10-28 |
Sumitomo Pharma America Inc |
2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
|
|
CN114450027A
(zh)
|
2019-08-16 |
2022-05-06 |
儿童医院医疗中心 |
用cdc42特异性抑制剂治疗受试者的方法
|
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|